Perspective Therapeutics Announces Clinical Collaboration with Merck

What Happened
On September 14, 2026, Perspective Therapeutics, Inc. (NASDAQ: CATX) announced a clinical collaboration and supply agreement with Merck. The company filed a Current Report on Form 8-K (Item 8.01) and attached a press release as Exhibit 99.1. The 8-K did not disclose financial terms or detailed operational specifics.

Key Details

• Filing date: September 14, 2026 (Form 8-K, Item 8.01 — Other Events).
• Agreement type: clinical collaboration and supply agreement with Merck (details not included in the 8-K).
• Press release: Filed as Exhibit 99.1 and incorporated by reference.
• Executive signature: Report signed by Johan (Thijs) Spoor, Chief Executive Officer of Perspective Therapeutics.

Why It Matters
A collaboration and supply agreement with a major pharmaceutical company like Merck is a notable development for a small biotech: it may validate Perspective’s programs and could affect clinical development or supply chain stability. Because the 8-K did not include terms, investors should monitor future company disclosures (press releases, additional SEC filings) for scope, financial terms, timelines, and any material impacts on revenue, expenses, or development plans.